Secretariat General DE LA Sante Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: Secretariat General DE LA Sante Pharmaceutical Import Records from India — 2 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Secretariat General DE LA Sante — Pharmaceutical Importer Profile (2026) | 2 Products, $1.8M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Secretariat General DE LA Sante?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ipca Laboratories Limited	$879.5K	18	53.3%
Macleods Pharmaceuticals Limited	$441.6K	11	26.7%
Strides Pharma Science Limited	$279.8K	11	16.9%
Mylan Laboratories Limited	$50.0K	1	3.0%

Secretariat General DE LA Sante sources from 4 verified Indian suppliers across 33 distinct formulations. The supply base is diversified across 4 suppliers, reducing single-source dependency risk.

What Formulations Does Secretariat General DE LA Sante Import?

Formulation	Value	Ships
Drugs & pharma. harmless medicines- macsunate aq forte (artesunate 100MG and amodiaquine 270MG tablet)	$140.0K	3
Harmless medicines-artesunate 60MG powder for injection 1 vial	$100.0K	2
Harmless medicines-artesunate/amodiaquine 100MG/270MG tablets 6 x 25 tablet	$100.0K	2
Artecap artesunate rectal capsules [100MG][soft gelatin](138,299.00x 1x2's)	$78.8K	3
Harmless medicines artesunate 60MG	$50.0K	1
Artemether 20MG + lumefantrine 120MG TAB	$50.0K	1
Harmless medicines artesunate amodiaquine 50MG 135MG tablets 3 x 25 tablets

What Products Does Secretariat General DE LA Sante Import?

Top Products by Import Value

1Artesunate$1.4M 2Artemether$400.0K

Secretariat General DE LA Sante Therapeutic Categories — 1 Specializations

Secretariat General DE LA Sante imports across 1 therapeutic categories, with Antimalarial & Antiparasitic (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Antimalarial & Antiparasitic

2 products · 100.0% · $1.8M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Artesunate	Antimalarial & Antiparasitic	$1.4M	27	0.7%	2
2	Artemether	Antimalarial & Antiparasitic	$400.0K	8	0.0%	3

Key Metrics

Total Import Value$1.8M

Products2

Shipments35

Categories1

CountryCongo Dr

#1 Rankings0

Indian Suppliers4

Formulations33

Top Categories

Antimalarial & Antiparasitic100.0%

Indian Suppliers

Last updated: March 28, 2026

Secretariat General DE LA Sante — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Secretariat General DE LA Sante is a governmental entity operating within the Ministry of Public Health, Hygiene, and Prevention of the Democratic Republic of Congo (DRC). It functions as the central procurement and distribution arm for pharmaceuticals, ensuring the availability of essential medicines across the country. Headquartered in Kinshasa, the capital city, the Secretariat General DE LA Sante plays a pivotal role in managing the national pharmaceutical supply chain, coordinating with various stakeholders to meet the healthcare needs of the Congolese population.

As a government procurement agency, its primary responsibility is to import, store, and distribute pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections. This centralized approach aims to streamline the supply chain, reduce costs, and maintain consistent quality standards for medicines distributed throughout the DRC. By overseeing the entire process—from importation to distribution—the Secretariat General DE LA Sante ensures equitable access to essential healthcare products nationwide.

2Distribution Network

The Secretariat General DE LA Sante operates a centralized distribution system from its main warehouse in Kinshasa, strategically located to serve as the primary hub for pharmaceutical imports and distribution. This centralization facilitates efficient management of inventory and ensures timely delivery of medicines to various regions within the DRC. While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, the centralized model suggests a focus on optimizing supply chain operations from the capital.

Supplier Relationship Intelligence — Secretariat General DE LA Sante

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The Secretariat General DE LA Sante's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.8 million USD from India across 35 shipments. This concentration is further emphasized by the top five imported products—Artesunate and Artemether—accounting for 100% of the portfolio. Such dependency on a limited number of suppliers and products can pose risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or logistical challenges.

However, this sourcing pattern may also reflect a strategic choice aimed at ensuring consistent quality and availability of critical antimalarial medications. The Secretariat General DE LA Sante's reliance on a select group of suppliers suggests established relationships and trust in the quality of products sourced from these manufacturers. Nonetheless, the lack of diversification in both suppliers and product categories indicates a potential vulnerability in the supply chain that could be addressed by exploring additional sourcing options and expanding the product portfolio.

2Supply Chain Resilience

The resilience of the Secretariat General DE LA Sante's supply chain is closely tied to its sourcing strategy. With a concentrated focus on two primary products—Artesunate and Artemether—sourced from four Indian suppliers, the supply chain's robustness is contingent upon the stability and reliability of these suppliers. The limited number of suppliers increases the risk of supply disruptions due to factors such as production issues, regulatory changes, or geopolitical tensions affecting trade routes.

To enhance supply chain resilience, it would be prudent for the Secretariat General DE LA Sante to consider diversifying its supplier base and expanding the range of imported pharmaceutical products. Engaging with additional suppliers and incorporating a broader spectrum of medications could mitigate risks associated with over-reliance on a narrow supply chain. Furthermore, establishing contingency plans and maintaining strategic stockpiles of essential medicines can provide a buffer against potential disruptions, ensuring continuous access to critical healthcare resources for the Congolese population.

3Strategic Implications

The Secretariat General DE LA Sante's concentrated sourcing pattern positions it as a key player in the DRC's pharmaceutical market, particularly in the antimalarial segment. This focus allows for streamlined procurement processes and potentially better pricing agreements with suppliers. However, the lack of diversification in both suppliers and product categories may limit the agency's ability to respond flexibly to changing healthcare needs and market dynamics.

For Indian exporters, the Secretariat General DE LA Sante represents a significant opportunity to strengthen their presence in the DRC market. By offering a wider range of pharmaceutical products and establishing relationships with additional suppliers, Indian companies can position themselves as reliable partners capable of meeting the diverse needs of the Congolese healthcare system. This strategic engagement could lead to increased market share and long-term partnerships within the DRC's pharmaceutical sector.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is the primary body responsible for regulating pharmaceutical activities in the DRC. ACOREP oversees the authorization and control of drug imports and exports, ensuring that all pharmaceutical products meet the country's safety, efficacy, and quality standards. This includes the registration of pharmaceutical products, inspection of manufacturing facilities, and monitoring of market activities to prevent the circulation of counterfeit or substandard medicines.

The regulatory framework governing pharmaceutical imports in the DRC is designed to protect public health by enforcing stringent standards for drug quality and safety. Importers must comply with ACOREP's requirements, which include obtaining necessary licenses, ensuring Good Manufacturing Practice (GMP) certification, and adhering to labeling and documentation standards. This regulatory oversight is crucial for maintaining the integrity of the pharmaceutical supply chain and safeguarding the health of the Congolese population.

2Import Licensing & GMP

Import licensing in the DRC requires importers to obtain authorization from ACOREP, which involves submitting detailed documentation about the pharmaceutical products, including certificates of analysis, GMP certificates, and proof of registration in the country of origin. While GMP certification is officially required, enforcement can be inconsistent; a Certificate of Pharmaceutical Product (CPP) is a critical document. Additionally, importers must undergo a pre-shipment inspection by authorized bodies, such as Bureau Veritas, for shipments valued over a certain threshold. These procedures are designed to ensure that imported pharmaceuticals meet the DRC's quality and safety standards.

Wholesale distribution authorization is also mandatory for entities involved in the distribution of pharmaceutical products within the DRC. This authorization ensures that distributors operate in compliance with national regulations, maintaining the integrity of the pharmaceutical supply chain and ensuring that medicines reach healthcare facilities and patients in optimal condition.

3Quality & Labeling

Pharmaceutical products imported into the DRC are subject to quality control measures to verify their safety and efficacy. Initial screening is conducted locally using methods like the GPHF Minilab, with more comprehensive analysis performed at WHO-prequalified laboratories abroad. This multi-tiered approach aims to detect and prevent the circulation of counterfeit or substandard medicines within the country.

Labeling requirements stipulate that all documentation and labeling be in French, the official language of the DRC. This includes product labels, package inserts, and promotional materials. Adherence to these labeling standards is essential for regulatory compliance and effective communication with healthcare professionals and patients.

4Recent Regulatory Changes

Between 2024 and 2026, the DRC has implemented several regulatory changes affecting pharmaceutical imports. ACOREP has been in the process of assuming responsibilities from the Directorate of Pharmacy and Medicine (DPM), including regulating clinical trials and authorizing and controlling drug imports and exports. This transition aims to streamline regulatory processes and enhance the efficiency of pharmaceutical oversight in the country. Additionally, there have been updates to import licensing procedures, emphasizing the need for comprehensive documentation and adherence to international quality standards. These changes reflect the DRC's commitment to improving the quality and safety of pharmaceutical products available to its citizens.

TransData Nexus Research · Congo Dr regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Secretariat General DE LA Sante identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Secretariat General DE LA Sante's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 35 individual customs records matching Secretariat General DE LA Sante.
5.Supplier Verification: Secretariat General DE LA Sante sources from 4 verified Indian suppliers across 33 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Secretariat General DE LA Sante

Secretariat General DE LA Sante — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Secretariat General DE LA Sante?

What Formulations Does Secretariat General DE LA Sante Import?

What Products Does Secretariat General DE LA Sante Import?

Top Products by Import Value

Secretariat General DE LA Sante Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Secretariat General DE LA Sante — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Secretariat General DE LA Sante

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Secretariat General DE LA Sante — Procurement Pattern Analysis

1Product Strategy

Frequently Asked Questions — Secretariat General DE LA Sante

What products does Secretariat General DE LA Sante import from India?

Who supplies pharmaceuticals to Secretariat General DE LA Sante from India?

What is Secretariat General DE LA Sante's total pharmaceutical import value?

What therapeutic categories does Secretariat General DE LA Sante focus on?

Get Full Secretariat General DE LA Sante Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology